Skip to main content
Clinical Trials/NCT06646653
NCT06646653RecruitingNot Applicable

Feasibility Clinical Study of the Alma System in Treating Primary Postpartum Hemorrhage

ResQ Medical Ltd1 site in 1 country10 target enrollmentStarted: April 14, 2024Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
10
Locations
1
Primary Endpoint
Rate of related SAEs

Study Overview

Brief Summary

Feasibility clinical study of the Alma System in treating primary postpartum hemorrhage (PPH).

Detailed Description

10 subjects, first in woman trial with ethics committee oversight. Women who experienced postpartum hemorrhage will be treated with the Alma System, which aims to rapidly reduce or stop the bleeding by targeting the primary cause: uterine atony.

The primary objective is to verify the safety of the Alma System in humans by: 1. Ensuring the absence of serious adverse events (SAEs) related to the use of the Alma System during and after the procedure. 2. Evaluating any observable damage to the uterus, cervix, or vagina due to the use of the Alma System. 3. Evaluating the occurrence of uterine inversion or folding during the use of the Alma System.

The secondary objectives include evaluating: 1. The ability to easily place the Alma System trans-vaginally. 2. The ability to connect the Alma System to a vacuum source and maintain the desired negative pressure. 3. The ability of the Alma System to contract the uterus to a level that reduces or stops blood loss and avoids further non-surgical and surgical intervention. 4. The time from insertion and start of negative pressure to a visible reduction in blood loss.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adult Female, 18 years of age or older at time of consent.
  • Subject or her legally authorized representative is able to understand and provide consent to participate in the clinical investigation.
  • Subjects who present with an atonic uterus for at least 10 minutes after expulsion of placenta with failure to obtain contraction and/or Subjects who have lost blood post-vaginal delivery > = 500 ml and lost blood post-cesarian delivery > = 1000 ml and according to the Investigator's judgment, require an intervention.
  • Failed first-line intervention of uterotonics and uterine massage/bimanual uterine massage to stop bleeding.

Exclusion Criteria

  • Subjects who do not provide informed consent to participate in the clinical investigation.
  • Subjects who deliver at a uterus size < 34 weeks.
  • Subjects who have lost > 1000 ml of blood for vaginal birth and > 2000 ml for caesarian delivery.
  • Subjects who have abnormal PT, PTT and INR.
  • Subjects who present with retained placenta, uterine lacerations, or for any other conditions outside of atonic post-partum hemorrhage.
  • PPH that the investigator determines to require more aggressive treatment, including any of the following:
  • Hysterectomy;
  • B-lynch suture;
  • Uterine artery embolization or ligation;
  • Hypogastric ligation;
  • Known uterine anomaly;
  • Ongoing intrauterine pregnancy.
  • Placental abnormality including any of the following:
  • Known placenta accreta;
  • Retained placenta with known risk factors for placenta accreta (e.g., history of prior uterine surgery, including prior c-section and placenta previa);
  • Retained placenta without easy manual removal.
  • Known uterine rupture
  • Unresolved uterine inversion.

Outcomes

Primary Outcomes

Rate of related SAEs

Time Frame: 6 weeks

Rate of device related SAEs up to six weeks following device treatment

Rate of Damage to Cervix, Uterus or Vagina

Time Frame: Procedure

Rate of any observable damage to cervix, uterus or vagina during or immediately after device procedure

Rate of Occurrence of Uterine Inversion or Folding

Time Frame: Procedure

Rate of occurrence of uterine inversion or folding during or immediately after device procedure

Secondary Outcomes

  • Rate of Uterine Contraction(Procedure)
  • Time to Visible Reduction in Blood Flow(Procedure)
  • User Feedback on Connection to Vacuum(Procedure)
  • User Feedback on Placement of Alma(Procedure)

Investigators

Sponsor
ResQ Medical Ltd
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Feasibility Clinical Study of the Alma... | Clinical Trial